Engage Therapeutics is developing Staccato alprazolam for the immediate termination of an active epileptic seizure, or Rapid Epileptic Seizure Termination (REST). The Company anticipates advancing Staccato alprazolam to a Phase 3 registration trial in
2020.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.